

# Gema Moreno-Bueno

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4803973/gema-moreno-bueno-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

118  
papers

11,666  
citations

53  
h-index

107  
g-index

121  
ext. papers

13,079  
ext. citations

8.2  
avg, IF

5.79  
L-index

#	Paper	IF	Citations
118	Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. <i>Nature Medicine</i> , <b>2012</b> , 18, 883-91	50.5	2530
117	Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. <i>Cancer Research</i> , <b>2008</b> , 68, 989-97	10.1	823
116	Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. <i>Cancer Cell</i> , <b>2012</b> , 22, 709-24	24.3	692
115	Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. <i>Oncogene</i> , <b>2002</b> , 21, 3241-6	9.2	478
114	Transcriptional regulation of cell polarity in EMT and cancer. <i>Oncogene</i> , <b>2008</b> , 27, 6958-69	9.2	459
113	Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. <i>Cancer Research</i> , <b>2006</b> , 66, 9543-56	10.1	259
112	Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 6487-501	12.9	257
111	Abnormalities of the APC/beta-catenin pathway in endometrial cancer. <i>Oncogene</i> , <b>2002</b> , 21, 7981-90	9.2	228
110	beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. <i>American Journal of Pathology</i> , <b>1999</b> , 155, 527-36	5.8	195
109	Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. <i>Modern Pathology</i> , <b>2007</b> , 20, 474-81	9.8	179
108	Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. <i>Journal of Pathology</i> , <b>2011</b> , 223, 72-80	9.4	175
107	Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. <i>Oncogene</i> , <b>2004</b> , 23, 3272-83	9.2	167
106	The morphological and molecular features of the epithelial-to-mesenchymal transition. <i>Nature Protocols</i> , <b>2009</b> , 4, 1591-613	18.8	165
105	SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. <i>Cancer Research</i> , <b>2007</b> , 67, 11721-31	10.1	160
104	Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. <i>Cancer Research</i> , <b>2008</b> , 68, 4541-50	10.1	158
103	Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. <i>International Journal of Cancer</i> , <b>2003</b> , 106, 208-15	7.5	149
102	EMT: Present and future in clinical oncology. <i>Molecular Oncology</i> , <b>2017</b> , 11, 718-738	7.9	148

101	Tiling path genomic profiling of grade 3 invasive ductal breast cancers. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2711-22	12.9	138
100	Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. <i>EMBO Molecular Medicine</i> , <b>2011</b> , 3, 528-44	12	130
99	Endometrial carcinoma: molecular alterations involved in tumor development and progression. <i>Oncogene</i> , <b>2013</b> , 32, 403-13	9.2	126
98	Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. <i>Cancer Management and Research</i> , <b>2014</b> , 6, 205-16	3.6	123
97	beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. <i>Diagnostic Molecular Pathology</i> , <b>2001</b> , 10, 116-22		120
96	Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. <i>Molecular Cancer</i> , <b>2010</b> , 9, 196	42.1	119
95	beta-catenin expression in pilomatrixomas. Relationship with beta-catenin gene mutations and comparison with beta-catenin expression in normal hair follicles. <i>British Journal of Dermatology</i> , <b>2001</b> , 145, 576-81	4	114
94	Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. <i>Oncogene</i> , <b>2007</b> , 26, 2902-13	9.2	108
93	Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. <i>Journal of Pathology</i> , <b>2003</b> , 199, 471-8	9.4	107
92	Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. <i>Cancer Research</i> , <b>2007</b> , 67, 1927-34	10.1	95
91	The class I bHLH factors E2-2A and E2-2B regulate EMT. <i>Journal of Cell Science</i> , <b>2009</b> , 122, 1014-24	5.3	94
90	Cyclin D1 gene (CCND1) mutations in endometrial cancer. <i>Oncogene</i> , <b>2003</b> , 22, 6115-8	9.2	88
89	Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. <i>Cancer</i> , <b>2001</b> , 92, 2829-36	6.4	88
88	Snai1 and Snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines. <i>Oncogene</i> , <b>2008</b> , 27, 4690-701	9.2	86
87	Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 5846-5859	10.1	84
86	Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. <i>Journal of Clinical Pathology</i> , <b>2007</b> , 60, 1006-12	3.9	78
85	Prostaglandin E2 Leads to the Acquisition of DNMT3A-Dependent Tolerogenic Functions in Human Myeloid-Derived Suppressor Cells. <i>Cell Reports</i> , <b>2017</b> , 21, 154-167	10.6	76
84	The EMT signaling pathways in endometrial carcinoma. <i>Clinical and Translational Oncology</i> , <b>2012</b> , 14, 715-20	3.6	76

83	The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. <i>Modern Pathology</i> , <b>2001</b> , 14, 650-4	9.8	74
82	Exosome-mimetic nanoplateforms for targeted cancer drug delivery. <i>Journal of Nanobiotechnology</i> , <b>2019</b> , 17, 85	9.4	73
81	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. <i>Molecular Cancer</i> , <b>2014</b> , 13, 223	42.1	72
80	EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination. <i>Oncogene</i> , <b>2015</b> , 34, 2609-20	9.2	71
79	LOXL2 in epithelial cell plasticity and tumor progression. <i>Future Oncology</i> , <b>2012</b> , 8, 1095-108	3.6	71
78	Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107, djv077	9.7	69
77	Gasdermin-B promotes invasion and metastasis in breast cancer cells. <i>PLoS ONE</i> , <b>2014</b> , 9, e90099	3.7	67
76	Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). <i>American Journal of Surgical Pathology</i> , <b>2005</b> , 29, 1322-9	6.7	67
75	Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization. <i>Oncogene</i> , <b>2015</b> , 34, 951-64	9.2	65
74	Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. <i>Human Pathology</i> , <b>2006</b> , 37, 1042-9	3.7	63
73	Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. <i>International Journal of Cancer</i> , <b>2006</b> , 119, 1164-75	7.5	61
72	LOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway. <i>Scientific Reports</i> , <b>2017</b> , 7, 44988	4.9	60
71	Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. <i>American Journal of Surgical Pathology</i> , <b>2009</b> , 33, 1157-63	6.7	60
70	High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary. <i>Journal of Pathology</i> , <b>2006</b> , 208, 708-13	9.4	60
69	Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. <i>Breast Cancer Research and Treatment</i> , <b>2007</b> , 102, 157-72	4.4	59
68	A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. <i>Journal of Pathology</i> , <b>2014</b> , 232, 319-29	9.4	58
67	Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression. <i>EMBO Journal</i> , <b>2015</b> , 34, 1090-109	13	56
66	A novel human ghrelin variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential pathophysiological relevance. <i>PLoS ONE</i> , <b>2011</b> , 6, e23302	3.7	54

65	JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. <i>Oncogene</i> , <b>2008</b> , 27, 5033-44	9.2	53
64	Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. <i>American Journal of Surgical Pathology</i> , <b>2007</b> , 31, 501-8	6.7	53
63	MicroRNA-dependent regulation of transcription in non-small cell lung cancer. <i>PLoS ONE</i> , <b>2014</b> , 9, e905247	4.7	53
62	The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. <i>Oncogene</i> , <b>2012</b> , 31, 2049-61	9.2	52
61	Functional characterization of E- and P-cadherin in invasive breast cancer cells. <i>BMC Cancer</i> , <b>2009</b> , 9, 74	4.8	50
60	Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. <i>Journal of Pathology</i> , <b>2003</b> , 201, 589-95	9.4	48
59	Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2001</b> , 438, 464-9	5.1	48
58	Zeb1 and Snail1 engage miR-200f transcriptional and epigenetic regulation during EMT. <i>International Journal of Cancer</i> , <b>2015</b> , 136, E62-73	7.5	41
57	LOXL2 catalytically inactive mutants mediate epithelial-to-mesenchymal transition. <i>Biology Open</i> , <b>2014</b> , 3, 129-37	2.2	40
56	E47 and Id1 interplay in epithelial-mesenchymal transition. <i>PLoS ONE</i> , <b>2013</b> , 8, e59948	3.7	39
55	beta-catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2000</b> , 437, 599-604	5.1	38
54	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 56295-56308	3.3	38
53	Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 12962-7	11.5	36
52	MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. <i>Oncogene</i> , <b>2019</b> , 38, 6035-6050	9.2	34
51	Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4846-4858	12.9	32
50	Tissue microarray immunohistochemical expression analysis of mismatch repair (hMLH1 and hMSH2 genes) in endometrial carcinoma and atypical endometrial hyperplasia: relationship with microsatellite instability. <i>Modern Pathology</i> , <b>2003</b> , 16, 1148-58	9.8	32
49	Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer. <i>Journal of Pathology</i> , <b>2017</b> , 241, 475-487	9.4	31
48	Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 1863-73	7.5	30

47	KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. <i>American Journal of Pathology</i> , <b>2011</b> , 178, 1529-43	5.8	30
46	Molecular alterations associated with cyclin D1 overexpression in endometrial cancer. <i>International Journal of Cancer</i> , <b>2004</b> , 110, 194-200	7.5	30
45	Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. <i>EBioMedicine</i> , <b>2016</b> , 10, 137-49	8.8	29
44	Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. <i>Human Pathology</i> , <b>2013</b> , 44, 244-54	3.7	28
43	The tumor suppressor ING1 contributes to epigenetic control of cellular senescence. <i>Aging Cell</i> , <b>2011</b> , 10, 158-71	9.9	28
42	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. <i>Oncogene</i> , <b>2017</b> , 36, 2737-2749	9.2	27
41	Therapeutic targeting of HER2-CBR heteromers in HER2-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 3863-3872	11.5	27
40	MicroRNAs as prognostic markers in ovarian cancer. <i>Molecular and Cellular Endocrinology</i> , <b>2014</b> , 390, 73-84	4.4	27
39	Contribution of Epithelial Plasticity to Therapy Resistance. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	26
38	Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5SDFUR in breast cancer MCF7 cells. <i>Biochemical Pharmacology</i> , <b>2006</b> , 72, 1646-56	6	25
37	Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells. <i>Oncotarget</i> , <b>2015</b> , 6, 38239-56	3.3	25
36	PAI-1 and functional blockade of SNAI1 in breast cancer cell migration. <i>Breast Cancer Research</i> , <b>2008</b> , 10, R100	8.3	22
35	Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 1551-1563	7.5	21
34	Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers. <i>Modern Pathology</i> , <b>2017</b> , 30, 134-145	9.8	21
33	Sin3b interacts with Myc and decreases Myc levels. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 22221-36	5.4	21
32	Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. <i>Modern Pathology</i> , <b>2008</b> , 21, 925-36	9.8	19
31	Low frequency of BRAF mutations in endometrial and in cervical carcinomas. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 3865; author reply 3865-6	12.9	19
30	A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 532-543	6.1	19

29	Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	16
28	Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas. <i>Lung Cancer</i> , <b>2001</b> , 34, 67-74	5.9	15
27	A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer. <i>Modern Pathology</i> , <b>2015</b> , 28, 1492-503	9.8	14
26	ING4 regulates a secretory phenotype in primary fibroblasts with dual effects on cell proliferation and tumor growth. <i>Oncogene</i> , <b>2014</b> , 33, 1945-53	9.2	14
25	A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. <i>Human Pathology</i> , <b>2014</b> , 45, 2394-403	3.7	13
24	"New" molecular taxonomy in breast cancer. <i>Clinical and Translational Oncology</i> , <b>2008</b> , 10, 777-85	3.6	13
23	The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. <i>Oncotarget</i> , <b>2016</b> , 7, 60110-60122	3.3	13
22	Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression. <i>BMC Cancer</i> , <b>2015</b> , 15, 940	4.8	12
21	The Ras-related gene ERAS is involved in human and murine breast cancer. <i>Scientific Reports</i> , <b>2018</b> , 8, 13038	4.9	11
20	Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	10
19	In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines. <i>Carcinogenesis</i> , <b>2018</b> , 39, 447-457	4.6	10
18	Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences. <i>Pathobiology</i> , <b>2018</b> , 85, 35-40	3.6	10
17	The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes. <i>Oncogene</i> , <b>2016</b> , 35, 3485-94	9.2	10
16	Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	10
15	Characterisation of tumoral markers correlated with ErbB2 (HER2/Neu) overexpression and metastasis in breast cancer. <i>Proteomics - Clinical Applications</i> , <b>2008</b> , 2, 1313-26	3.1	8
14	Circulating Tumor Cells Characterization Revealed TIMP1 as a Potential Therapeutic Target in Ovarian Cancer. <i>Cells</i> , <b>2020</b> , 9,	7.9	7
13	Re: Scholten et al. Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma. <i>J Pathol</i> 2003; 201: 460-465. <i>Journal of Pathology</i> , <b>2004</b> , 202, 511-2	9.4	7
12	Impact of notch signaling on the prognosis of patients with head and neck squamous cell carcinoma. <i>Oral Oncology</i> , <b>2020</b> , 110, 105003	4.4	7

11	Loss of Snail2 favors skin tumor progression by promoting the recruitment of myeloid progenitors. <i>Carcinogenesis</i> , <b>2015</b> , 36, 585-97	4.6	5
10	Cancer network activity associated with therapeutic response and synergism. <i>Genome Medicine</i> , <b>2016</b> , 8, 88	14.4	5
9	Prostaglandin F-induced Prostate Transmembrane Protein, Androgen Induced 1 mediates ovarian cancer progression increasing epithelial plasticity. <i>Neoplasia</i> , <b>2019</b> , 21, 1073-1084	6.4	5
8	Biological Effects of Temozolomide on the mTOR Pathway in Endometrial Carcinoma: A Pharmacodynamic Phase II Study. <i>International Journal of Gynecological Cancer</i> , <b>2016</b> ,	3.5	4
7	Insight updating of the molecular hallmarks in ovarian carcinoma. <i>European Journal of Cancer, Supplement</i> , <b>2020</b> , 15, 16-26	1.6	4
6	Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients. <i>Clinical Epigenetics</i> , <b>2021</b> , 13, 52	7.7	4
5	Loxl3 Promotes Melanoma Progression and Dissemination Influencing Cell Plasticity and Survival.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	4
4	Isolation and characterization of casein kinase I from Dictyostelium discoideum. <i>Biochemical Journal</i> , <b>2000</b> , 349, 527-37	3.8	3
3	Isobolographic Analysis Demonstrates the Additive and Synergistic Effects of Gemcitabine Combined with Fucoidan in Uterine Sarcomas and Carcinosarcoma Cells. <i>Cancers</i> , <b>2019</b> , 12,	6.6	3
2	E2A Modulates Stemness, Metastasis, and Therapeutic Resistance of Breast Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 4529-4544	10.1	3
1	Gemcitabine and Selected mTOR Inhibitors in Uterine Sarcomas and Carcinosarcoma Cells- an Isobolographic Analysis. <i>International Journal of Medical Sciences</i> , <b>2020</b> , 17, 2987-2997	3.7	2